Arpa, Giovanni
Fassan, Matteo
Guerini, Camilla
Quaquarini, Erica
Grillo, Federica
Angerilli, Valentina
Guzzardo, Vincenza
Lonardi, Sara
Bergamo, Francesca
Lenti, Marco Vincenzo
Pedrazzoli, Paolo
Paulli, Marco
Di Sabatino, Antonio
Vanoli, Alessandro http://orcid.org/0000-0002-2976-7032
Funding for this research was provided by:
Fondazione IRCCS Policlinico San Matteo
Ministero della Salute (NET-2016–02363853)
Associazione Italiana per la Ricerca sul Cancro (ID. 22759 program)
Article History
Received: 22 April 2022
Revised: 15 July 2022
Accepted: 27 July 2022
First Online: 4 August 2022
Declarations
:
: This study was approved by the Ethics Committee of Pavia (protocol number: 20140003980). Informed consent was obtained for all patients enrolled in the study.
: Matteo Fassan reports personal fees (as speaker bureau or advisor) from Roche, MSD, GSK, Astellas Pharma, Diaceutics and received research grants from Astellas Pharma, QED therapeutics and macrophage pharma, unrelated to the current work. Giovanni Arpa, Camilla Guerini, Erica Quaquarini, Federica Grillo, Valentina Angerilli, Vincenza Guzzardo, Sara Lonardi, Francesca Bergamo, Marco Vincenzo Lenti, Paolo Pedrazzoli, Marco Paulli, Antonio Di Sabatino and Alessandro Vanoli have no financial or non-financial interests to declare that are relevant to the content of this article.